Capital International Investors Reduces $822M in Danaher Corporation ($DHR)
The fund trimmed its Danaher holdings, now holding 14 million shares valued at $2.75 billion.
Key Points
- Capital International Investors cut its stake in Danaher Corporation by 23.2%, reducing its holdings by about 4.2 million shares.
- Danaher's stock traded near $196.05 on Friday, with a market cap of $136.7 billion and a P/E ratio of 37.4.
- Insider buying was observed with multiple purchases, and analysts have set varied price targets, with a consensus recommendation of 'strong buy'.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Capital International Investors has reduced its stake in Danaher Corporation (NYSE: DHR) by 23.2%, according to its latest Form 13F filing with the SEC. The fund sold 4,231,295 shares, leaving it with 14,014,713 shares valued at approximately $2.75 billion. This filing reflects their holdings as of the reporting period and may not represent their current position.
Capital International Investors vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in Capital International Investors' Danaher Position
Capital International Investors cut its holdings in Danaher from 18,246,008 shares to 14,014,713 shares, a decrease of 23.2%. The shares are now valued at about $2.75 billion, down from their previous value. This significant reduction shows a strategic shift in the fund's portfolio.
Other Institutional Activity in Danaher
Other major institutional investors have also made moves in Danaher. BlackRock, Inc. slightly reduced its position by 396,733 shares, ending with 51,640,619 shares valued at $9.79 billion. Vanguard Capital Management LLC opened a new position with 41,127,810 shares worth approximately $7.80 billion. State Street Corp increased its holdings by 212,847 shares to a total of 27,894,181 shares, valued at $5.30 billion. Meanwhile, FMR LLC added 3,027,600 shares, bringing its total to 22,534,329 shares, worth about $4.27 billion. JPMorgan Chase & Co reduced its stake significantly by 4,667,877 shares, leaving it with 16,917,649 shares valued at $3.11 billion.
Danaher Corporation Stock Down 10.1%
Shares of NYSE:DHR traded near $196.05 on Friday. Danaher Corporation boasts a market cap of $136.7 billion and a P/E ratio of 37.4. The stock's 52-week range has been between $160.93 and $242.80. It currently has a 50-day moving average of $178.79 and a 200-day moving average of $203.93. The company maintains a current ratio of 1.87 and a quick ratio of 1.40, with a debt-to-equity ratio of 37.17.
$DHR stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Danaher's recent earnings report showed revenue of $24.78 billion, with a growth rate of 3.7%. The company's earnings per share stood at $5.16, with a net margin of 14.9% and a return on equity of 7.1%. The next earnings report is scheduled for July 21, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 5.3%. Revenue missed estimates by 1.8%.
-
Profit surprise
EBITDA missed by 22 percent. Operating income missed by 23 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 5 target cuts.
-
Earnings quality
Gross margin down 1.1 points. Positive free cash flow.
Earnings Call Summary
Danaher started 2026 solidly with adjusted earnings per share of $2.06, up 9.5 percent year over year, beating the consensus of $1.95. Revenue came in at $5.951 billion, slightly below the $6.057 billion expected, due mainly to a lighter respiratory season at Cepheid being down roughly 25 percent. However, strong bioprocessing momentum, with consumables up high single digits and equipment orders surging over 30 percent year over year for the first time in nearly two years, offset weakness. Diagnostics and Life Sciences showed pockets of improvement, with Beckman Coulter diagnostics growing mid single digits outside China and newer products like the Xpert GI panel gaining traction.
Guidance Management raised full year adjusted earnings per share to $8.35 to $8.55 from the prior range. Revenue guidance remains 3 percent to 6 percent growth for the full year, with lower respiratory sales of $1.6 billion to $1.7 billion offset by better core growth elsewhere. Second quarter expected to show low single digit core revenue growth with operating margins around 26.5 percent.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Danaher pays an annual dividend rate of $1.60, yielding 0.83% with a payout ratio of 26.36%. The ex-dividend date has not been specified.
Insider Buying and Selling at Danaher Corporation
Recent insider activity at Danaher includes several purchases on May 15, 2026. Charles Lamanna, Shane Sanders, Linda Filler, and Alan Spoon each bought 1,699 shares, while Sanders and Filler also purchased an additional 680 shares each. These transactions were not part of a planned trading program.
Analysts Set New Price Targets
On June 11, 2026, Piper Sandler initiated coverage of Danaher with a 'hold' rating and a $200 price target. HSBC maintained a 'buy' rating with a $230 target on June 3, 2026. Citigroup reinstated its 'buy' rating with a $230 target on May 27, 2026, while also downgrading it to 'hold' with a $95 target on the same day. RBC Capital reinstated a 'buy' rating with a $200 target on May 15, 2026. The consensus among 23 analysts is a 'strong buy' with a mean target price of $242.35.
About Danaher Corporation
Danaher Corporation, headquartered in Washington, DC, designs and markets professional, medical, and industrial products globally. The company operates in the Biotechnology, Life Sciences, and Diagnostics segments, offering a range of technologies and services for therapeutics development, lab solutions, and diagnostic tools. Led by CEO Rainer M. Blair, Danaher employs around 58,000 people worldwide.
Bottom Line
Capital International Investors' decision to cut its stake in Danaher Corporation highlights shifting strategies among institutional investors. Danaher's stock remains a focus due to its significant market presence in the healthcare sector. Investors will be watching closely for any further changes in holdings and analyst ratings as the next earnings report approaches. Remember, 13F filings are backward-looking and may not reflect the current position of the fund.
Get Danaher Corporation alerts
New 13F filings, insider trades, and analyst moves on $DHR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.